MAPT and supranuclear palsy, progressive, 1: Tau targeting therapeutics in PSP under current investigation, such as the tau aggregation inhibitors anle138b [7–9] and NPT088 [10, 11] as well as anti-Tau monoclonal antibodies like Gosuranemab [12, 13] and UCB0107 [14, 15], showed promising results and would probably profit from a reliable tau biomarker in potential phase II and phase III studies.